European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation.
biomarkers
chronic kidney disease
hepatocellular carcinoma
liver transplantation
recurrent primary diseases
rejection
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
03
2023
accepted:
25
07
2023
medline:
18
9
2023
pubmed:
15
9
2023
entrez:
15
9
2023
Statut:
epublish
Résumé
Currently, one-year survival following liver transplantation (LT) exceeds 90% in large international registries, and LT is considered definitive treatment for patients with end-stage liver disease and liver cancer. Recurrence of disease, including hepatocellular carcinoma (HCC), significantly hampers post-LT outcomes. An optimal approach to immunosuppression (IS), including safe weaning, may benefit patients by mitigating the effect on recurrent diseases, as well as reducing adverse events associated with over-/under-IS, including chronic kidney disease (CKD). Prediction of these outcome measures-disease recurrence, CKD, and immune status-has long been based on relatively inaccurate clinical models. To address the utility of new biomarkers in predicting these outcomes in the post-LT setting, the European Society of Organ Transplantation (ESOT) and International Liver Transplant Society (ILTS) convened a working group of experts to review literature pertaining to primary disease recurrence, development of CKD, and safe weaning of IS. Summaries of evidence were presented to the group of panelists and juries to develop guidelines, which were discussed and voted in-person at the Consensus Conference in Prague November 2022. The consensus findings and recommendations of the Liver Working Group on new biomarkers in LT, clinical applicability, and future needs are presented in this article.
Identifiants
pubmed: 37711401
doi: 10.3389/ti.2023.11358
pii: 11358
pmc: PMC10498996
doi:
Substances chimiques
Biomarkers
0
Types de publication
Consensus Development Conference
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11358Informations de copyright
Copyright © 2023 Berenguer, de Martin, Hessheimer, Levitsky, Maluf, Mas, Selzner, Hernàndez-Èvole, Lutu, Wahid and Zubair.
Déclaration de conflit d'intérêts
JL is advisor for Eurofins and advisor/speaker for Mallinckrodt. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Transplant. 2022 Feb;22(2):532-540
pubmed: 34510731
Front Immunol. 2019 Apr 24;10:873
pubmed: 31068943
Ann Surg. 2022 Nov 1;276(5):868-874
pubmed: 35916378
Clin Transplant. 2015 Feb;29(2):161-6
pubmed: 25522890
Liver Transpl. 2009 Nov;15 Suppl 2:S25-34
pubmed: 19876939
Liver Transpl. 2009 Mar;15(3):330-40
pubmed: 19243003
Am J Transplant. 2021 Oct;21(10):3312-3323
pubmed: 33783969
Liver Transpl. 2009 Oct;15(10):1254-61
pubmed: 19790153
Am J Transplant. 2019 Dec;19(12):3250-3262
pubmed: 31162867
Transplant Direct. 2019 Jun 21;5(7):e462
pubmed: 31334336
Br J Cancer. 2015 Feb 3;112(3):532-8
pubmed: 25584485
Am J Transplant. 2013 Apr;13(4):1110-1111
pubmed: 23433321
Liver Transpl. 2007 Jan;13(1):80-90
pubmed: 16964594
J Hepatol. 2014 Aug;61(2):286-92
pubmed: 24713190
Transplantation. 2003 Dec 15;76(11):1583-8
pubmed: 14702528
J Investig Med. 2018 Jun;66(5):1-6
pubmed: 29632031
J Hepatol. 2021 Dec;75(6):1409-1419
pubmed: 34437910
Liver Transpl. 2022 Jun;28(6):1024-1038
pubmed: 34919754
Lancet. 2007 Jul 7;370(9581):59-67
pubmed: 17617273
Best Pract Res Clin Gastroenterol. 2011 Dec;25(6):765-82
pubmed: 22117641
Am J Transplant. 2016 Apr;16(4):1285-93
pubmed: 26603835
Transplantation. 2008 Jan 15;85(1):81-7
pubmed: 18192916
Liver Int. 2021 Mar;41(3):562-573
pubmed: 33205544
Hepatology. 2000 Oct;32(4 Pt 1):693-700
pubmed: 11003612
Oncol Lett. 2018 Apr;15(4):5481-5488
pubmed: 29552189
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Clin Gastroenterol Hepatol. 2013 Dec;11(12):1667-72
pubmed: 23872669
J Hepatol. 2006 Apr;44(4):702-9
pubmed: 16473433
Hepatology. 2020 May;71(5):1775-1786
pubmed: 31509263
Transplantation. 2011 Mar 27;91(6):684-9
pubmed: 21248661
World J Gastroenterol. 2018 Nov 21;24(43):4939-4949
pubmed: 30487703
Transplant Direct. 2021 Jun 10;7(7):e714
pubmed: 34131586
J Clin Invest. 2008 Aug;118(8):2845-57
pubmed: 18654667
Am J Gastroenterol. 2010 Mar;105(3):613-20
pubmed: 20040915
Am J Transplant. 2011 Sep;11(9):1972-8
pubmed: 21794091
Gut. 2003 Jun;52(6):893-7
pubmed: 12740348
Liver Transpl. 2001 Apr;7(4):302-10
pubmed: 11303289
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
Hepatology. 2017 Jan;65(1):269-280
pubmed: 27533743
Am J Transplant. 2016 Sep;16(9):2532-44
pubmed: 26932352
J Clin Invest. 2012 Jan;122(1):368-82
pubmed: 22156196
J Cancer. 2021 Oct 22;12(23):7190-7200
pubmed: 34729120
J Hepatol. 2022 Jul;77(1):84-97
pubmed: 35143897
Hum Immunol. 2018 May;79(5):362-372
pubmed: 29402484
Front Oncol. 2022 Aug 11;12:940473
pubmed: 36033451
J Hepatol. 2019 Aug;71(2):313-322
pubmed: 31071367
Clin Gastroenterol Hepatol. 2023 Jan;21(1):45-54.e6
pubmed: 34801743
Asian J Surg. 2022 Jan;45(1):435-440
pubmed: 34426060
Best Pract Res Clin Gastroenterol. 2017 Apr;31(2):187-198
pubmed: 28624107
Transplant Proc. 2006 Dec;38(10):3636-9
pubmed: 17175353
Gut Liver. 2022 May 15;16(3):443-455
pubmed: 34737243
Liver Transpl. 2003 Dec;9(12):1231-43
pubmed: 14625822
N Engl J Med. 2003 Sep 4;349(10):931-40
pubmed: 12954741
Liver Transpl. 2013 Sep;19(9):937-44
pubmed: 23784747
Transplant Proc. 2015 Jan-Feb;47(1):93-6
pubmed: 25645780
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
Liver Transpl. 2005 Oct;11(10):1252-7
pubmed: 16184542
Ann Surg. 2023 Feb 1;277(2):e359-e365
pubmed: 34928553
Transpl Int. 2007 Jul;20(7):576-82
pubmed: 17425725
Transplant Direct. 2021 Nov 05;7(12):e784
pubmed: 34778544
Clin Immunol. 2010 Dec;137(3):337-46
pubmed: 20822959
Nat Rev Gastroenterol Hepatol. 2020 Mar;17(3):139-152
pubmed: 31792430
Hepatology. 2020 Aug;72(2):569-583
pubmed: 31721246
Hepatology. 2018 Jan;67(1):123-133
pubmed: 28802062
Liver Transpl. 2016 Jan;22(1):34-41
pubmed: 26335026
Hepatol Commun. 2022 Apr;6(4):710-727
pubmed: 34725972
Gut. 2020 Nov;69(11):2025-2034
pubmed: 32883873
J Hepatol. 1995 Dec;23(6):674-80
pubmed: 8750166
Oncotarget. 2016 Apr 12;7(15):19824-39
pubmed: 26918346
Hum Immunol. 2010 Mar;71(3):274-6
pubmed: 20006667
Hepatology. 2001 Jan;33(1):22-7
pubmed: 11124816
Sci Transl Med. 2014 Jun 25;6(242):242ra81
pubmed: 24964989
Clin Gastroenterol Hepatol. 2020 Dec;18(13):2879-2902.e9
pubmed: 32289533
J Hepatol. 1999 Nov;31(5):929-38
pubmed: 10580593
Transplantation. 2020 Jun;104(6):1143-1149
pubmed: 32217940
Liver Transpl. 2008 Feb;14(2):245-51
pubmed: 18236405
Ann Surg. 2021 Mar 1;273(3):483-493
pubmed: 33065633
Hepatology. 2019 Mar;69(3):1273-1286
pubmed: 30229989
PLoS Med. 2017 Apr 25;14(4):e1002286
pubmed: 28441386
Hepat Mon. 2011 Mar;11(3):195-9
pubmed: 22087143
Liver Int. 2015 Jul;35(7):1893-901
pubmed: 25515948
Cancers (Basel). 2021 Aug 27;13(17):
pubmed: 34503144
Clin Exp Immunol. 2022 Jan 28;207(1):123-139
pubmed: 35020854
Ann Transl Med. 2020 Sep;8(17):1067
pubmed: 33145286
Transplantation. 2018 May;102(5):809-815
pubmed: 29300232
Hepatology. 2013 Nov;58(5):1824-35
pubmed: 23532679
Liver Transpl. 2000 Sep;6(5):570-4
pubmed: 10980055
Transpl Immunol. 2015 Oct;33(2):110-6
pubmed: 26225458
Transpl Int. 2021 Aug;34(8):1455-1467
pubmed: 34028110
Liver Transpl. 2020 Jan;26(1):141-159
pubmed: 31610081
Transplantation. 2019 Jan;103(1):57-67
pubmed: 30335694
Hepatology. 1999 Nov;30(5):1121-7
pubmed: 10534330
Transpl Int. 2022 Oct 24;35:10915
pubmed: 36406781